Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
Rhea-AI Summary
Foghorn Therapeutics (Nasdaq: FHTX) announced management will present at the Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026. The company presentation is scheduled for Wednesday, February 11, 2026 at 3:00 p.m. EST by Adrian Gottschalk, President and CEO.
A live webcast will be available via the company’s Investors "Events & Presentations" page and will remain accessible for 30 days. Management will also conduct one-on-one meetings at the summit.
Positive
- None.
Negative
- None.
News Market Reaction – FHTX
In the Feb 3 session, FHTX declined 2.74%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 13 | Direct financing | Positive | +4.7% | Closed $50M registered direct financing at a 30% premium. |
| Jan 09 | Financing & pipeline | Positive | +23.6% | Announced $50M equity financing and cash runway into first half 2028. |
| Nov 25 | Conference participation | Neutral | +3.5% | Participation in 8th Annual Evercore Healthcare Conference with webcast access. |
| Nov 05 | Earnings update | Positive | +13.3% | Q3 2025 update with $180.3M cash and multiple degrader programs advancing. |
| Nov 03 | Investor conferences | Neutral | -4.5% | Announcement of participation in three November 2025 investor conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent financing, pipeline, and corporate updates have generally coincided with positive price reactions, while neutral conference-participation news has shown mixed impact.
Over the last few months, Foghorn reported multiple financing and pipeline milestones. A $50 million registered direct financing at a 30% premium and a January update highlighting an estimated $208.9 million cash position and runway into the first half of 2028 both saw strong positive reactions. Conference participation and the Q3 2025 update also drew gains, with only one investor-conference announcement coinciding with a decline, framing today’s Guggenheim summit news within an active investor-engagement pattern.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Emerging Outlook: Biotech Summit, being held February 11-12, 2026, in New York, NY. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Presentation Date and Time: Wednesday February 11, 2026, at 3:00 p.m. EST
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Please find a link to the webcast here
- Management will also participate in one-on-one meetings
A webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 30 days.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary, scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc. khellsvik@foghorntx.com
